Literature DB >> 17687709

The role of one-carbon metabolism in schizophrenia and depression.

Frances Rachel Frankenburg1.   

Abstract

OBJECTIVE: Physicians often check folate and cobalamin levels in patients with schizophrenia and depression. The reasons for this practice are reviewed, as well as implications for treatment.
METHOD: The physiology of the one-carbon cycle, involving folate, cobalamin, homocysteine, S-adenosyl-methionine, and methylene tetrahydrofolate reductase (MTHFR) is first reviewed, and then the particular contributions of folate and B12 are reviewed. PubMed was searched for studies of the association between folate, cobalamin, homocysteine, and MTHFR polymorphisms and schizophrenia and depression.
RESULTS: The recent key studies from the large literature addressing these topics are summarized. Treatment implications are discussed.
CONCLUSION: It is important to check folate and B12 levels in certain situations, such as alcoholism, malnutrition, malabsorption, and the concurrent use of some medications. Checking homocysteine and methylmalonic levels might be useful. With respect to treatment, folate and cobalamin deficiencies should be corrected. Cobalamin supplementation is probably not helpful. Folate supplementation is indicated in pregnancy but may exacerbate the effects of cobalamin deficiency. SAMe may prove to be a useful antidepressant. In the future, screening for MTHFR polymorphisms might be useful.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17687709     DOI: 10.1080/10673220701551136

Source DB:  PubMed          Journal:  Harv Rev Psychiatry        ISSN: 1067-3229            Impact factor:   3.732


  23 in total

1.  Metabolic imbalance associated with methylation dysregulation and oxidative damage in children with autism.

Authors:  Stepan Melnyk; George J Fuchs; Eldon Schulz; Maya Lopez; Stephen G Kahler; Jill J Fussell; Jayne Bellando; Oleksandra Pavliv; Shannon Rose; Lisa Seidel; David W Gaylor; S Jill James
Journal:  J Autism Dev Disord       Date:  2012-03

2.  Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics.

Authors:  Vicki L Ellingrod; Stephan F Taylor; Gregory Dalack; Tyler B Grove; Michael J Bly; Robert D Brook; Sebastian K Zöllner; Rodica Pop-Busui
Journal:  J Clin Psychopharmacol       Date:  2012-04       Impact factor: 3.153

3.  Epigenetic mechanisms in the pathophysiology of psychotic disorders.

Authors:  W Brad Ruzicka
Journal:  Harv Rev Psychiatry       Date:  2015 May-Jun       Impact factor: 3.732

4.  Dietary B vitamin intake and incident premenstrual syndrome.

Authors:  Patricia O Chocano-Bedoya; JoAnn E Manson; Susan E Hankinson; Walter C Willett; Susan R Johnson; Lisa Chasan-Taber; Alayne G Ronnenberg; Carol Bigelow; Elizabeth R Bertone-Johnson
Journal:  Am J Clin Nutr       Date:  2011-02-23       Impact factor: 7.045

5.  Promoter methylation and tissue-specific transcription of the α7 nicotinic receptor gene, CHRNA7.

Authors:  Andrew Canastar; Judith Logel; Sharon Graw; Jessica Finlay-Schultz; Christina Osborne; Milda Palionyte; Carla Drebing; Molly Plehaty; Lisa Wilson; Rosemary Eyeson; Sherry Leonard
Journal:  J Mol Neurosci       Date:  2011-11-04       Impact factor: 3.444

6.  Decreased serum pyridoxal levels in schizophrenia: meta-analysis and Mendelian randomization analysis.

Authors:  Yukiko Tomioka; Shusuke Numata; Makoto Kinoshita; Hidehiro Umehara; Shin-Ya Watanabe; Masahito Nakataki; Yoshimi Iwayama; Tomoko Toyota; Masashi Ikeda; Hidenaga Yamamori; Shinji Shimodera; Atsushi Tajima; Ryota Hashimoto; Nakao Iwata; Takeo Yoshikawa; Tetsuro Ohmori
Journal:  J Psychiatry Neurosci       Date:  2018-05       Impact factor: 6.186

7.  Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia.

Authors:  Joshua L Roffman; David G Brohawn; Adam Z Nitenson; Eric A Macklin; Jordan W Smoller; Donald C Goff
Journal:  Schizophr Bull       Date:  2011-10-20       Impact factor: 9.306

8.  DNA methylation in schizophrenia subjects: gender and MTHFR 677C/T genotype differences.

Authors:  Kyle J Burghardt; J Richard Pilsner; Michael J Bly; Vicki L Ellingrod
Journal:  Epigenomics       Date:  2012-06       Impact factor: 4.778

9.  Methylenetetrahydrofolate reductase (MTHFR) polymorphism susceptibility to schizophrenia and bipolar disorder: an updated meta-analysis.

Authors:  Cai-Yun Hu; Zhen-Zhong Qian; Feng-Feng Gong; Shan-Shan Lu; Fang Feng; Yi-Le Wu; Hui-Yun Yang; Ye-Huan Sun
Journal:  J Neural Transm (Vienna)       Date:  2014-06-18       Impact factor: 3.575

10.  Influence of the MTHFR C677T polymorphism on magnetic resonance imaging hyperintensity volume and cognition in geriatric depression.

Authors:  Edmund D Hong; Warren D Taylor; Douglas R McQuoid; Guy G Potter; Martha E Payne; Allison Ashley-Koch; David C Steffens
Journal:  Am J Geriatr Psychiatry       Date:  2009-10       Impact factor: 4.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.